Total Payments
$367,085
2024 Payments
$124,349
Companies
31
Transactions
539
Medicare Patients
1,937
Medicare Billing
$198,937
Payment Breakdown by Category
Other$271,550 (74.0%)
Consulting$39,951 (10.9%)
Travel$39,047 (10.6%)
Food & Beverage$15,352 (4.2%)
Education$761.66 (0.2%)
Research$425.00 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Honoraria | $271,550 | 69 | 74.0% |
| Consulting Fee | $39,951 | 29 | 10.9% |
| Travel and Lodging | $39,047 | 137 | 10.6% |
| Food and Beverage | $15,352 | 293 | 4.2% |
| Education | $761.66 | 10 | 0.2% |
| Unspecified | $425.00 | 1 | 0.1% |
Payments by Type
General
$366,660
538 transactions
Research
$425.00
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| UROGEN PHARMA, INC. | $346,917 | 346 | $0 (2024) |
| Janssen Biotech, Inc. | $4,706 | 15 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $3,681 | 7 | $0 (2024) |
| Boston Scientific Corporation | $2,373 | 38 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $2,300 | 2 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $2,226 | 2 | $0 (2021) |
| Intuitive Surgical, Inc. | $748.23 | 10 | $0 (2019) |
| COLOPLAST CORP | $575.30 | 65 | $0 (2024) |
| Dendreon Pharmaceuticals LLC | $534.85 | 6 | $0 (2022) |
| Astellas Pharma US Inc | $511.71 | 7 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $124,349 | 129 | UROGEN PHARMA, INC. ($115,524) |
| 2023 | $127,461 | 145 | UroGen Pharma, Inc. ($126,543) |
| 2022 | $28,239 | 71 | UroGen Pharma, Inc. ($27,095) |
| 2021 | $80,677 | 134 | UROGEN PHARMA, INC. ($77,754) |
| 2020 | $2,718 | 9 | E.R. Squibb & Sons, L.L.C. ($2,300) |
| 2019 | $438.16 | 8 | Boston Scientific Corporation ($292.01) |
| 2018 | $2,168 | 27 | Intuitive Surgical, Inc. ($724.47) |
| 2017 | $1,035 | 16 | BOSTON SCIENTIFIC CORPORATION ($422.59) |
All Payment Transactions
539 individual payment records from CMS Open Payments — Page 1 of 22
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/06/2024 | Ferring Pharmaceuticals Inc. | ADSTILADRIN (Biological) | Food and Beverage | In-kind items and services | $79.80 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2024 | Ferring Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $53.35 | General |
| 12/05/2024 | Ferring Pharmaceuticals Inc. | ADSTILADRIN (Biological) | Food and Beverage | In-kind items and services | $37.49 | General |
| Category: ONCOLOGY | ||||||
| 12/04/2024 | UROGEN PHARMA, INC. | JELMYTO (Drug) | Food and Beverage | In-kind items and services | $177.48 | General |
| Category: UROTHELIAL CANCER | ||||||
| 12/04/2024 | UROGEN PHARMA, INC. | JELMYTO (Drug) | Food and Beverage | In-kind items and services | $23.37 | General |
| Category: UROTHELIAL CANCER | ||||||
| 11/08/2024 | UROGEN PHARMA, INC. | JELMYTO (Drug) | Consulting Fee | Cash or cash equivalent | $2,200.00 | General |
| Category: UROTHELIAL CANCER | ||||||
| 11/07/2024 | UROGEN PHARMA, INC. | JELMYTO (Drug) | Food and Beverage | In-kind items and services | $171.98 | General |
| Category: UROTHELIAL CANCER | ||||||
| 10/22/2024 | Ferring Pharmaceuticals Inc. | ADSTILADRIN (Biological) | Food and Beverage | In-kind items and services | $20.73 | General |
| Category: ONCOLOGY | ||||||
| 09/17/2024 | Ferring Pharmaceuticals Inc. | ADSTILADRIN (Biological) | Food and Beverage | In-kind items and services | $31.95 | General |
| Category: ONCOLOGY | ||||||
| 09/05/2024 | Janssen Scientific Affairs, LLC | — | Travel and Lodging | In-kind items and services | $689.56 | General |
| 09/05/2024 | Janssen Scientific Affairs, LLC | — | Travel and Lodging | Cash or cash equivalent | $425.00 | General |
| 09/05/2024 | Janssen Scientific Affairs, LLC | — | Travel and Lodging | Cash or cash equivalent | $334.17 | General |
| 09/05/2024 | Janssen Scientific Affairs, LLC | — | Travel and Lodging | In-kind items and services | $162.72 | General |
| 09/04/2024 | Janssen Scientific Affairs, LLC | — | Food and Beverage | Cash or cash equivalent | $41.23 | General |
| 08/28/2024 | UROGEN PHARMA, INC. | JELMYTO (Drug) | Consulting Fee | Cash or cash equivalent | $4,200.00 | General |
| Category: UROTHELIAL CANCER | ||||||
| 08/28/2024 | UROGEN PHARMA, INC. | JELMYTO (Drug) | Travel and Lodging | Cash or cash equivalent | $17.99 | General |
| Category: UROTHELIAL CANCER | ||||||
| 08/27/2024 | Ferring Pharmaceuticals Inc. | ADSTILADRIN (Biological) | Food and Beverage | In-kind items and services | $27.00 | General |
| Category: ONCOLOGY | ||||||
| 07/31/2024 | UROGEN PHARMA, INC. | JELMYTO (Drug) | Food and Beverage | In-kind items and services | $184.31 | General |
| Category: UROTHELIAL CANCER | ||||||
| 07/30/2024 | Ferring Pharmaceuticals Inc. | ADSTILADRIN (Biological) | Food and Beverage | In-kind items and services | $31.87 | General |
| Category: ONCOLOGY | ||||||
| 07/26/2024 | UROGEN PHARMA, INC. | JELMYTO (Drug) | Honoraria | Cash or cash equivalent | $4,400.00 | General |
| Category: UROTHELIAL CANCER | ||||||
| 07/26/2024 | UROGEN PHARMA, INC. | JELMYTO (Drug) | Food and Beverage | In-kind items and services | $111.29 | General |
| Category: UROTHELIAL CANCER | ||||||
| 07/25/2024 | UROGEN PHARMA, INC. | JELMYTO (Drug) | Honoraria | Cash or cash equivalent | $6,800.00 | General |
| Category: UROTHELIAL CANCER | ||||||
| 07/25/2024 | UROGEN PHARMA, INC. | JELMYTO (Drug) | Travel and Lodging | In-kind items and services | $951.46 | General |
| Category: UROTHELIAL CANCER | ||||||
| 07/25/2024 | UROGEN PHARMA, INC. | JELMYTO (Drug) | Travel and Lodging | In-kind items and services | $650.93 | General |
| Category: UROTHELIAL CANCER | ||||||
| 07/25/2024 | UROGEN PHARMA, INC. | JELMYTO (Drug) | Travel and Lodging | Cash or cash equivalent | $502.40 | General |
| Category: UROTHELIAL CANCER | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| VECTOR EVALUATION | COVIDIEN LP | $425.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 492 | 4,213 | $725,450 | $83,564 |
| 2022 | 15 | 492 | 647 | $210,333 | $39,446 |
| 2021 | 15 | 516 | 683 | $222,133 | $44,221 |
| 2020 | 13 | 437 | 549 | $166,608 | $31,707 |
Total Patients
1,937
Total Services
6,092
Medicare Billing
$198,937
Procedure Codes
57
All Medicare Procedures & Services
57 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Office | 2023 | 77 | 116 | $275,152 | $26,299 | 9.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 90 | 137 | $51,375 | $11,268 | 21.9% |
| 51720 | Instillation of anti-cancer drug into bladder | Office | 2023 | 21 | 100 | $96,500 | $8,322 | 8.6% |
| J9030 | Bcg live intravesical instillation, 1 mg | Office | 2023 | 18 | 3,408 | $34,080 | $7,738 | 22.7% |
| 52240 | Destruction and/or removal of large growth of bladder using an endoscope | Facility | 2023 | 14 | 20 | $95,403 | $7,021 | 7.4% |
| 52235 | Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | Facility | 2023 | 25 | 26 | $61,698 | $6,862 | 11.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 42 | 46 | $25,300 | $5,274 | 20.8% |
| 52234 | Destruction and/or removal of growth of bladder and urethra using an endoscope, 0.5-2.0 cm | Office | 2023 | 16 | 19 | $38,513 | $4,276 | 11.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 28 | 28 | $27,916 | $4,161 | 14.9% |
| 81002 | Urinalysis, manual test | Office | 2023 | 91 | 231 | $6,930 | $787.71 | 11.4% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 12 | 14 | $3,780 | $717.57 | 19.0% |
| 51798 | Ultrasound measurement of bladder capacity after voiding | Office | 2023 | 30 | 32 | $6,176 | $334.72 | 5.4% |
| 74420 | Imaging of urinary tract following injection of a contrast agent | Facility | 2023 | 15 | 15 | $2,175 | $326.40 | 15.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 13 | 21 | $452.00 | $176.40 | 39.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 176 | 228 | $37,176 | $9,765 | 26.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 66 | 86 | $20,794 | $5,950 | 28.6% |
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Facility | 2022 | 60 | 104 | $52,931 | $5,602 | 10.6% |
| 52240 | Destruction and/or removal of large growth of bladder using an endoscope | Facility | 2022 | 12 | 13 | $21,450 | $3,902 | 18.2% |
| 52235 | Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | Facility | 2022 | 13 | 16 | $18,912 | $3,091 | 16.3% |
| 52332 | Insertion of stent in ureter using an endoscope | Facility | 2022 | 15 | 24 | $22,470 | $2,409 | 10.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 24 | 24 | $7,872 | $1,688 | 21.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2022 | 31 | 31 | $6,382 | $1,616 | 25.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 14 | 27 | $4,833 | $1,476 | 30.5% |
| 55700 | Biopsy of prostate gland | Facility | 2022 | 13 | 13 | $7,220 | $1,197 | 16.6% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 15 | 15 | $3,750 | $1,168 | 31.1% |
About Dr. Katie Murray, D.O
Dr. Katie Murray, D.O is a Urology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/13/2009. The National Provider Identifier (NPI) number assigned to this provider is 1235372715.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Katie Murray, D.O has received a total of $367,085 in payments from pharmaceutical and medical device companies, with $124,349 received in 2024. These payments were reported across 539 transactions from 31 companies. The most common payment nature is "Honoraria" ($271,550).
As a Medicare-enrolled provider, Murray has provided services to 1,937 Medicare beneficiaries, totaling 6,092 services with total Medicare billing of $198,937. Data is available for 4 years (2020–2023), covering 57 distinct procedure/service records.
Ad
Practice Information
- Specialty Urology
- Other Specialties Urology
- Location New York, NY
- Active Since 04/13/2009
- Last Updated 04/06/2023
- Taxonomy Code 208800000X
- Entity Type Individual
- NPI Number 1235372715
Products in Payments
- JELMYTO (Drug) $327,371
- OPDIVO (Biological) $2,300
- ERLEADA (Drug) $2,203
- IMFINZI (Biological) $2,148
- Da Vinci Surgical System (Device) $748.23
- LITHOVUE (Device) $742.68
- AMS (Device) $667.75
- PROVENGE (Drug) $534.85
- SpeediCath (Device) $525.96
- LIGASURE (Device) $425.00
- ADSTILADRIN (Biological) $318.51
- LithoVue (Device) $243.00
- AMS 700 CXR RTE KIT (Device) $152.25
- Kerecis Omega3 SurgiClose (Device) $150.62
- GENTLECATH (Device) $146.58
- AQUABEAM SYSTEM (Device) $146.20
- General - Erectile Dysfunction (Device) $134.04
- ZYTIGA (Drug) $108.44
- rezum Generator (Device) $92.34
- General - Kidney Stone Disease (Device) $88.98
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Urology Doctors in New York
Mr. Michael Grasso, Md, MD
Urology — Payments: $742,907
Urology $742,907
Robert Valenzuela, Md, MD
Urology — Payments: $642,070
Urology $642,070
Dr. Neil Bander, M.d, M.D
Urology — Payments: $540,525
Urology $540,525
Dr. Benjamin Brucker, Md, MD
Urology — Payments: $454,774
Urology $454,774
Dr. Ketan Badani, M.d, M.D
Urology — Payments: $308,393
Urology $308,393
Ojas Shah, M.d, M.D
Urology — Payments: $241,835
Urology $241,835